Sfoglia per AUTORE
MASSUTí B
Collezione AOU San Luigi di Orbassano
Items : 2
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.
2024
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Leighl NB; Akamatsu H; Lim SM; Cheng Y; Minchom AR; Marmarelis ME; Sanborn RE; Chih-Hsin Yang J; Liu B; John T; Massutí B; Spira AI; Lee SH; Wang J; Li J; Liu C; Novello S; Kondo M; Tamiya M; Korbenfeld E; Moskovitz M; Han JY; Alexander M; Joshi R; Felip E; Voon PJ; Danchaivijitr P; Hsu PC; Silva Melo Cruz FJ; et alii...
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2022 Oct;172:94-99. doi: 10.1016/j.lungcan.2022.08.008. Epub 2022 Aug 12.
2022
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Felip E; Smit EF; Molina-Vila MA; Dafni U; Massuti B; Berghmans T; de Marinis F; Passiglia F; Dingemans AC; Cobo M; Viteri S; Britschgi C; Cuffe S; Provencio M; Merkelbach-Bruse S; Andriakopoulou C; Kammler R; Ruepp B; Roschitzki-Voser H; Peters S; Wolf J; Stahel R;